Nodofree (Dorzolamide Hydrochloride)

Dorzolamide Hydrochloride, the active ingredient in Nodofree, is a carbonic anhydrase inhibitor presented as an ophthalmic solution for ocular administration. It is used to lower intra‑ocular pressure in adults with primary open‑angle glaucoma or ocular hypertension, helping to preserve visual function and prevent disease progression.

GNH USA supplies Nodofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and research institutions, ensuring rigorous quality and regulatory compliance.

Dorzolamide Hydrochloride is used in ocular hypotensive therapy to manage conditions associated with elevated intra‑ocular pressure. Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Glaucoma (any type): provides intra‑ocular pressure reduction as part of combination therapy.

Common Side Effects: - Ocular burning or stinging upon instillation. - Transient blurred vision. - Altered taste sensation. - Eye discomfort or itching. - Headache. - Redness of the conjunctiva.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Corneal edema or keratitis. - Persistent eye pain. - Sudden loss of vision. - Stevens‑Johnson syndrome or toxic epidermal necrolysis (rare).

Before using Nodofree, consider the following precautions: Pregnancy: consult a healthcare professional before use. Breastfeeding: weigh potential risks and benefits. Contact lens wearers: may experience discomfort; consider removing lenses before instillation. Systemic carbonic anhydrase inhibition: monitor renal function in patients with pre‑existing kidney disease. Allergy: avoid if known hypersensitivity to sulfonamides. Store at room temperature: keep in the original container, protect from light and moisture.

Dorzolamide may interact with other ocular or systemic agents. Review the following interaction categories: Major Interactions (Avoid): - Concurrent use of systemic carbonic anhydrase inhibitors (additive hypotensive effect). - Combination with topical beta‑blockers (excessive intra‑ocular pressure reduction). - Oral sulfonamide antibiotics (risk of cross‑reactivity). Moderate Interactions (Monitor Closely): - Co‑administration with topical steroids (potential increase in intra‑ocular pressure). - Use with other ocular hypotensives (adjust dosing to avoid over‑lowering pressure). - Anticholinergic eye drops (possible ocular surface irritation).